Corvus Pharmaceuticals Inc.

CRVS | NASDAQ

Price Alert Chart Builder DCF Calculator

$12.57

+$0.15 (+1.21%)

Sep 22, 2026, 9:44 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $1.04B

Enterprise Value $829.9M

Beta 0.86

Average Volume 1.24M

Shares Outstanding (Diluted) 92.37M

Shares Change YoY 18.76%

Institutional Ownership 77.75%

Exchange NASDAQ

ISIN US2210151005

Price Performance

Price Change 1M -14.1%

Price Change 3M -1.7%

Price Change 6M -12.7%

Price Change YTD 69.7%

Price Change 1Y 105.6%

Price Change 3Y 711.8%

Price Change 5Y 82.7%

1M CAGR (ann.) -10.8%

1Y CAGR (ann.) 102.9%

5Y CAGR (ann.) 37.9%

All-Time CAGR -1.3%

Valuation

PE Ratio -19.41

Forward PE N/A

PEG Ratio 0.08

Forward PEG -0.80

PS Ratio N/A

Forward PS 275.70

PB Ratio 4.64

P/FCF Ratio -18.75

P/Adj. FCF Ratio -15.72

P/OCF Ratio -25.88

EV/Sales N/A

EV/EBIT -16.07

EV/EBITDA -16.12

EV/FCF -14.90

Earnings Yield -5.2%

FCF Yield -5.3%

Adj. FCF Yield -6.4%

Financial Health

Net Cash $215.23M

Total Debt $728K

Cash & Short-Term Investments $215.23M

Total Assets $239.27M

Current Ratio 16.16

Quick Ratio 16.16

Debt / Equity Ratio 0.00

Debt / EBITDA -0.01

Debt / FCF -0.01

OCF / Debt -75.42

Interest Coverage -31.93

Altman Z-Score 42.66

Piotroski F-Score 3

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -19.3%

Returns

Return on Assets -22.6%

Return on Equity -36.1%

Return on Invested Capital -25.2%

Return on Capital Employed -25.3%

Return on Tangible Assets -22.6%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y -13.6%

EPS CAGR 5Y 2.0%

EPS CAGR 10Y 17.1%

FCF CAGR 3Y -48.8%

FCF CAGR 5Y -17.5%

FCF CAGR 10Y 1.6%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 13

EPS Growth Next 3Y 16.1%

Revenue Growth Next 3Y N/A

Earnings Date Nov 2, 2026

EPS Estimate (next Q) -$0.21

EPS Growth Est (next Q) 75.0%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $40

Price Target Upside 222.1%

Cash Flow

Operating Cash Flow $-54.9M

Free Cash Flow $-55.69M

Adj. Free Cash Flow $-66.42M

FCF Per Share -$0.49

OCF Per Share -$0.48

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-55K

Operating Income $-56.96M

EBITDA $-51.49M

Net Income $-54.13M

EPS (Diluted) -$0.64

Revenue / Employee N/A

Profit / Employee $-1.46M

Employees 37